Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.75.

Several equities research analysts have recently issued reports on AUTL shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Jefferies Financial Group raised Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Mizuho lowered their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. Finally, Truist Financial raised Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors have recently modified their holdings of AUTL. Mak Capital One LLC lifted its stake in shares of Autolus Therapeutics by 53.5% in the 3rd quarter. Mak Capital One LLC now owns 26,017,616 shares of the company’s stock valued at $42,409,000 after purchasing an additional 9,062,518 shares during the last quarter. Schroder Investment Management Group lifted its stake in shares of Autolus Therapeutics by 133.7% in the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock valued at $13,409,000 after purchasing an additional 4,824,763 shares during the last quarter. Armistice Capital LLC lifted its stake in shares of Autolus Therapeutics by 30.0% in the 3rd quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after purchasing an additional 3,600,000 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Autolus Therapeutics by 108.1% in the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after purchasing an additional 1,054,458 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Autolus Therapeutics in the third quarter worth approximately $639,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Trading Up 5.4%

Shares of Autolus Therapeutics stock opened at $1.56 on Friday. The stock has a 50 day moving average of $1.57 and a 200 day moving average of $1.55. Autolus Therapeutics has a 12 month low of $1.18 and a 12 month high of $2.70. The firm has a market cap of $415.21 million, a PE ratio of -1.43 and a beta of 2.02.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The company had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. As a group, equities research analysts forecast that Autolus Therapeutics will post -0.97 earnings per share for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.